News
ICCC
10.77
-1.69%
-0.19
Weekly Report: what happened at ICCC last week (0803-0807)?
Weekly Report · 2d ago
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
Barchart · 6d ago
Weekly Report: what happened at ICCC last week (0727-0731)?
Weekly Report · 08/03 10:13
Weekly Report: what happened at ICCC last week (0720-0724)?
Weekly Report · 07/27 10:17
ImmuCell: First Defense With Better Execution
Seeking Alpha · 07/24 06:45
Weekly Report: what happened at ICCC last week (0713-0717)?
Weekly Report · 07/20 10:14
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH
NASDAQ · 07/13 11:17
Weekly Report: what happened at ICCC last week (0706-0710)?
Weekly Report · 07/13 10:16
ImmuCell Records Q2 Sales Of $7 Mln & 20% Rise For Six-Month Sales In Preliminary Results
NASDAQ · 07/10 14:39
ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand
NASDAQ · 07/10 13:45
ImmuCell reports preliminary Q2 sales increase of 11.5% to $7.2M
Seeking Alpha · 07/09 20:33
Immucell reports preliminary Q2 revenue $7.2M
TipRanks · 07/09 20:15
ImmuCell Q2 Total Product Sales Rises 12%
Benzinga · 07/09 20:07
Weekly Report: what happened at ICCC last week (0629-0703)?
Weekly Report · 07/06 10:19
Weekly Report: what happened at ICCC last week (0622-0626)?
Weekly Report · 06/29 10:14
The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell
NASDAQ · 06/26 09:26
Top Stock Reports for JPMorgan, Novartis & Qualcomm
NASDAQ · 06/25 20:33
Immucell CEO Makes Bold Move With Significant Personal Stock Purchase
TipRanks · 06/23 02:07
Monday 6/22 Insider Buying Report: NTST, ICCC
NASDAQ · 06/22 17:46
Weekly Report: what happened at ICCC last week (0615-0619)?
Weekly Report · 06/22 10:23
More
Webull provides a variety of real-time ICCC stock news. You can receive the latest news about Immucell through multiple platforms. This information may help you make smarter investment decisions.
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).